 Sinemet open-label study severe Parkinson disease Almost patients idiopathic Parkinson disease respond overall dosage time Sinemet attractive method gradual sustained release levodopa time physiological striatal dopamine receptors early stages disease study patients moderate Parkinson disease Sinemet period Eleven patients full year therapy subjects withdrawals subjects non-Parkinson disease-related illness therapeutic benefit minimal period therapeutic benefit severe dystonias overall levodopa dosage patients side-effects levodopa patients nocturnal benefit long-acting preparation patients study Slow onset action Sinemet early-morning immobility Sinemet standard Sinemet useful form adjunct therapy patients